All In Biotech

Drug Trial Radar · NCT03464019

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID Studies

Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,097 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,097

Actual

Start

Jun 18, 2018

Primary completion

Jan 20, 2023

Study completion Jan 20, 2023

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medpace, Inc.; IQVIA Biotech
First posted
Mar 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a three-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil nasal spray (NS) self-administered by participants who experienced an episode of paroxysmal supraventricular tachycardia (PSVT) in an at-home setting. NODE-301 Part 1 included participants that received the randomized study drug to treat an episode of PSVT until the 150th positively adjudicated PSVT episode. Part 2 (also referred as the RAPID study) included participants that did not receive the randomized study drug in Part 1 and newly enrolled participants until the 180th positively adjudicated PSVT episode in Part 2. The study continued for approximately 6 months after the 180th positively adjudicated PSVT episode in Part 2 and this extension is referred to as Part 3 (also referred to as RAPID Extension).

Conditions

  • Paroxysmal Supraventricular Tachycardia

Interventions

  • EtripamilDrug

    Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

  • PlaceboDrug

    Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

  • Etripamil Test DoseDrug

    During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration.Time frame: NODE-301 Part 1: Within 5 hours of start of study drug dosing. NODE-301 Parts 2 and 3: Within 30 minutes of start of study drug dosing.

Locations

161 sites in 9 countries. Site status is shown where the registry gives one.

  • Arizona Arrhythmia Research Center

    Phoenix, Arizona

  • Arkansas Cardiology

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Medvin Clinical Research

    Cerritos, California

  • North Coast Cardiolog

    Encinitas, California

  • Titan Medical Research - Oceanside

    Encinitas, California

  • Los Alamitos Cardiovascular

    Los Alamitos, California

  • Amicis Research Center - Northridge

    Northridge, California

  • RESPIRE Research

    Palm Springs, California

  • South Denver Cardiology Associates, P.C

    Littleton, Colorado

  • Cardiology Associates of Fairfield County

    Norwalk, Connecticut

  • FWD Clinical Research

    Boca Raton, Florida

  • Baptist Health Ambulatory Services d/b/a

    Jacksonville, Florida

  • United Health Research, LLC

    Miami, Florida

  • IACT Health

    Columbus, Georgia

  • Piedmont Heart Institute- Fayetteville

    Fayetteville, Georgia

  • Piedmont Heart Institute-Fayetteville

    Fayetteville, Georgia

  • Georgia Arrythmia Consultants&Research Institute

    Macon, Georgia

  • St. Luke's Idaho Cardiology Associates

    Boise, Idaho

  • Idaho Catalyst Clinical Research

    Idaho Falls, Idaho

  • AMITA Health Medical Group Heart & Vascular Elk Grpve Village

    Elk Grove Village, Illinois

  • Parkview Physicians Group - Cardiology

    Fort Wayne, Indiana

  • Mercy One Iowa Heart Center

    West Des Moines, Iowa

  • Clinical Trials of America, LLC - Monroe, LA

    West Monroe, Louisiana

  • MedStar Health Research Institute - Chesapeake Cardiovascular Associates

    Baltimore, Maryland

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • Revival Research Institute, LLC - Southgate, MI

    Southgate, Michigan

  • Mercy Research

    St Louis, Missouri

  • Cardiovascular Associates of the Delaware Valley - Elmer

    Elmer, New Jersey

  • Cardiovascular Associates of the Delaware Valley

    Haddon Heights, New Jersey

  • Atlantic Health System - Morristown Medical Center

    Morristown, New Jersey

  • Columbia University

    New York, New York

  • New York Presbyterian Hospital/Weill Cornell Medical Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Cary Research Group, LLC

    Cary, North Carolina

  • Sanger Heart and Vascular Institute

    Charlotte, North Carolina

  • The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute

    Charlotte, North Carolina

  • Hatton Institute for Research & Education, Trihealth, Inc. - Cardiology

    Cincinnati, Ohio

  • The Ohio State University (OSU) Wexner Medical Center

    Columbus, Ohio

  • Rama Research LLC

    Marion, Ohio

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.